Drugs / D-SUIV cH8/1N1+AS01
last change Mar 2020 re-read 2 minutes ago

D-SUIV cH8/1N1+AS01

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03275389 Sep 2017 → Mar 2020 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as D-SUIV cH8/1N1+AS01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03275389
Route Intramuscular “1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the...” NCT03275389